[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"unrecognized-condition\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:unrecognized-condition":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,41,68,90,111,137,165],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100463779","evaluate-df-003-in-ex-vivo-assays-using-peripheral-blood-mononuclear-cell-from-subjects-with-rosah-syndrome-100463779",false,"NCT05319132","Evaluate DF-003 in ex Vivo Assays Using Peripheral Blood Mononuclear Cell From Subjects With ROSAH Syndrome","A Phase 0 Study to Evaluate DF-003 in ex Vivo Assays Using Peripheral Blood Mononuclear Cells (PBMC) From Subjects With Retinal Dystrophy, Optic Nerve Edema, Splenomegaly, Anhidrosis and Headache (ROSAH) Syndrome.","ROSAH","Inclusion Criteria:\n\n* Male or female aged over 18\n* Patient with ROSAH syndrome with the confirm T237M mutation\n\nExclusion Criteria:\n\n* person under legal protection or under protectives measures\n* person unable to express consent\n* person in emergency situation (vital or not)\n* person infected by Human Immunodeficiency Virus and\u002For Hepatitis B Virus and\u002For Hepatitis C Virus","ALL","18 Years",{"count":20,"type":21},4,"ESTIMATED","OBSERVATIONAL","Alpha-1 kinase (ALPK1) has been reported as a potential causative gene for ROSAH Syndrome.\n\nGenetic variants including T237M have been found in ROSAH Syndrome patients. Our in-house study has found that T237M mutation leads to hyperactivity of ALPK1, which may be the cause of the inflammatory syndromes found in ROSAH Syndrome patients. We hypothesize that T237M mutation ALPK1 cause ROSAH Syndrome and an ALPK1 inhibitor can be a potential therapy for treating this disease. To test our hypothesis, we designed an experiment in which ex vivo peripheral blood mononuclear cells (PBMCs) from ROSAH Syndrome patients will be exposed to a potent ALPK1 inhibitor (DF-003) or placebo. We expect to see downregulation of activated inflammatory genes, chemokine\u002Fcytokines and acute phase proteins in the ROSAH Syndrome patient samples that are exposed DF-003.",[25],"Unrecognized Condition",[27],"ROSAH Syndrome.","RECRUITING","2025-08-07",{"date":31,"type":32},"2025-08-08","ACTUAL",{"date":34,"type":32},"2022-09-06",{"date":36,"type":21},"2028-05-06",{"name":38,"class":39},"Hospices Civils de Lyon","OTHER",5,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100577815","effects-of-lh-and-fsh-on-metabolic-regulation-in-cumulus-cells-100577815","NCT06803199","Effects of LH and FSH on Metabolic Regulation in Cumulus Cells","Investigation of the Combined Effects of Luteinizing Hormone and Follicle-Stimulating Hormone on Metabolic Regulation in Cumulus Cells","Inclusion Criteria:\n\n* Age 35-40 years\n* BMI 18-30 kg\u002Fm2\n* planning to undergo IVF cycles\n\nExclusion Criteria:\n\n* Primary ovarian insufficiency\n* history of oophorectomy\n* receiving oocyte donation\n* Chromosome anomaly\n* Congenital uterine anomaly\n* Severe intrauterine adhesion\n* Malignancy\n* Using hormone therapy or supplements in recent 3 months","FEMALE","35 Years","40 Years",{"count":52,"type":21},60,"INTERVENTIONAL",[55],"NA","The combined use of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) has improved IVF pregnancy rates in infertile women aged 35-40, but its mechanisms remain unclear. This prospective study will examine how FSH and LH combined treatment affects cumulus cell energy metabolism. Sixty participants will be divided into two groups receiving either combined therapy or FSH alone. The study will analyze patient characteristics, infertility history, and compare mitochondrial function in cumulus cells to evaluate treatment effectiveness.",[25],"2025-01-27",{"date":60,"type":32},"2025-01-31",{"date":62,"type":32},"2024-12-01",{"date":64,"type":21},"2027-12-31",{"name":66,"class":39},"Kaohsiung Veterans General Hospital.",1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":53,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":67},"100534770","titration-of-inspired-oxygen-to-decrease-the-incidence-of-postoperative-pulmonary-complications-100534770","NCT06243146","Titration of Inspired Oxygen to Decrease the Incidence of Postoperative Pulmonary Complications","Titration of Inspired Oxygen During One-lung Ventilation to Decrease the Incidence of Postoperative Pulmonary Complications: a Randomized Controlled Trial","Inclusion Criteria:\n\n* ① General anesthesia with left bronchial tube intubation; ② Age range from 18 to 80 years old; ③ 18 kg\u002Fm2 ≤ BMI ≤ 30 kg\u002Fm2; ④ ASA grade I to III; ⑤ Individuals willing to participate in research and sign an informed consent form.\n\nExclusion Criteria:\n\n* ① CT scan indicates preoperative pulmonary infection, atelectasis, and pneumothorax; ② History of respiratory system diseases (COPD, bronchiectasis, pulmonary alveoli, interstitial lung disease, etc.); ③ Previous history of lung surgery; ④ First second forced expiratory volume\u002Festimated value (FEV1%)\\\u003C60%; ⑤ PaO2\\\u003C60mmhg (1 mmhg=0.133 kpa) or PaO2\u002FFiO2\\\u003C300mmhg or SpO2\\\u003C90% in the suction state; ⑥ History of acute upper respiratory tract infection, acute lung injury, acute respiratory distress syndrome, or respiratory failure within 3 months prior to surgery; ⑦ Combined heart failure (NYHA heart function grading ≥ 3); ⑧ Previous history of stroke and cerebral infarction; ⑨ Severe liver dysfunction (liver failure or Child Pugh score B or C) Chronic renal failure (glomerular filtration rate\\\u003C30 ml\u002Fmin) Suffering from mental illness, etc., which is not suitable for the author; æ Individuals who have participated in other clinical trials as subjects within the three months prior to participating in the study The patient refused to participate in the study.","80 Years",{"count":77,"type":21},156,[55],"Lung cancer is with the highest incidence rate and mortality among people over 60 years old in China. Postoperative pulmonary complications (PPCs) is the most common complication after pneumonectomy, which has a significant impact on the short-term and long-term prognosis of patients, and is even the primary risk factor leading to early postoperative death. High fraction of inspired oxygen (FiO2) is an independent risk factor for PPCs, but it is difficult to achieve oxygenation while avoiding hyperxemia during one lung ventilation (OLV).\n\nWe will randomly divide patients who plan to undergo thoracoscopic pulmonary resection into two groups. During OLV, titration will be used to determine the optimal FiO2 for titration group while FiO2 of 80% will be used for mechanical ventilation for control group. The incidence of postoperative PPCs, hypoxia\u002Fhyperxemia, severity level of postoperative PPC, postoperative 30 day PPC, increased hospitalization costs, and prolonged hospital stay will be observed in both groups of patients.We will evaluate the effectiveness and safety of titrating inhaled oxygen concentration in lung protection during OLV.",[25],"2024-10-29",{"date":83,"type":32},"2024-10-31",{"date":85,"type":32},"2024-06-20",{"date":87,"type":21},"2025-12-31",{"name":89,"class":39},"Sichuan Provincial People's Hospital",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":97,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":53,"phases":100,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":107,"leadSponsor":109,"locationsCount":67},"100566960","topical-oral-anesthesia-adjuncts-in-conventional-intubation-on-first-pass-success-rate-100566960","NCT06661967","Topical Oral Anesthesia Adjuncts in Conventional Intubation on First-Pass Success Rate","Topical Oral Anesthesia Adjuncts in Conventional Intubation: A Randomized Controlled Trial Evaluating the Impact of Topical Oral Anesthesia on First-pass Success Rate","Inclusion Criteria:\n\n* Patients in emergency department that have indication for conventional intubation\n* Age \\> 18 yr\n\nExclusion Criteria:\n\n* Patient who undergo RSI\n* Patient who falls in cardiac arrest airway algorithm\n* Patient who is currently pregnancy\n* Known allergy to lidocaine",true,{"count":99,"type":21},110,[55],"This study aims to determine the first-pass success rate in video laryngoscopy and other parameters that topical anesthesia can affect during intubation.",[25],"2024-10-25",{"date":105,"type":32},"2024-10-28",{"date":103,"type":32},{"date":108,"type":21},"2026-04-30",{"name":110,"class":39},"Queen Savang Vadhana Memorial Hospital, Thailand",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":48,"minAge":49,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":53,"phases":121,"briefSummary":122,"conditions":123,"keywords":124,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":136,"locationsCount":67},"100558104","the-effect-of-melatonin-supplementation-on-cumulus-cells-and-ivf-outcomes-100558104","NCT06546774","The Effect of Melatonin Supplementation on Cumulus Cells and IVF Outcomes","The Effect of Melatonin Supplementation on Cumulus Cells and Reproductive Outcomes in Older Women Undergoing IVF Cycles","Inclusion Criteria:\n\n* Age 35-45 years\n* BMI 18-30 kg\u002Fm2\n* planning to undergo IVF cycles\n\nExclusion Criteria:\n\n* Primary ovarian insufficiency\n* history of oophorectomy\n* receiving oocyte donation\n* Chromosome anomaly\n* Congenital uterine anomaly\n* Severe intrauterine adhesion\n* Malignancy\n* Using hormone therapy or supplements in recent 3 months","45 Years",{"count":120,"type":21},200,[55],"This study investigates the effects of melatonin supplementation on cumulus cell gene expression and in vitro fertilization (IVF) outcomes in women over 35 years old. In the study group, patients will receive melatonin supplementation for at least two months prior to their IVF cycles. Cumulus cells will be collected after oocyte retrieval, and IVF outcomes will be assessed.",[25],[125,126,127,128,129],"Melatonin","Cumulus cells","In vitro fertilization","Old women","Infertility","2024-08-09",{"date":132,"type":32},"2024-08-13",{"date":134,"type":32},"2021-05-01",{"date":87,"type":21},{"name":66,"class":39},{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":97,"sex":144,"minAge":145,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":53,"phases":149,"briefSummary":150,"conditions":151,"keywords":152,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":164,"locationsCount":67},"100542217","male-supplements-for-sperm-quality-and-aging-100542217","NCT06339996","Male Supplements for Sperm Quality and Aging","To Investigate Supplements for Improving Male Sperm Quality and Combating Aging","Inclusion Criteria:\n\n* Not meet the criteria of the 6th edition of the WHO manual for human semen analysis\n* BMI:18-30 kg\u002Fm2\n\nExclusion Criteria:\n\n* Azoospermia\n* Varicocele\n* Chromosome anomaly\n* Malignancy\n* Using hormone therapy or supplements in recent 3 months","MALE","30 Years","50 Years",{"count":148,"type":21},50,[55],"This study investigates the effects of a new supplement on sperm quality in men with poor sperm quality. Fifty patients will receive the supplement for three months, followed by semen analysis and assessment of sperm aging and mitochondrial function. Changes in sexual function and aging symptoms will also be evaluated.",[25],[153,154,155,156,157],"Male supplement","Sperm quality","Aging","Mitochondrial function","Sexual function","2024-08-01",{"date":160,"type":32},"2024-08-02",{"date":162,"type":32},"2024-03-26",{"date":87,"type":21},{"name":66,"class":39},{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":174,"conditions":175,"keywords":176,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":184,"leadSponsor":185,"locationsCount":4},"100553521","effectivity-gas-extraction-to-prevent-anesthesiologists-waste-gas-exposure-of-sevofluorane-during-pediatric-induction-100553521","NCT06487169","Effectivity Gas Extraction to Prevent Anesthesiologists Waste Gas Exposure of Sevofluorane During Pediatric Induction","Effectivity of the Air Extraction to Prevent Anesthesiologists Waste Anesthetic Gas Exposure of Sevoflurane During Pediatric Induction","Inclusion Criteria: anesthesiologists that work in pediatric anesthesia room performed induction anesthesia with sevoflurane delivery by mask -\n\nExclusion Criteria: anesthesia that required IV induction and that not use sevoflurane\n\n\\-",{"count":173,"type":21},10,"Inhalational anesthetics (IAs) are widely used in surgery and experimental research. IAs, in addition to their medical significance, are a major source of chemical contamination in the operating rooms (ORs).Exposure to IAs in ORs personnel results in reproductive effects, including infertility , spontaneous abortions , congenital diseases , psychological and neurological disturbances, hepatotoxicity , and genotoxicity .The metabolites of sevoflurane include hexafluoroisopropanol (HFIP) and inorganic fluoride (IF). The hospital's engineering department installed an air extractor with the objective to reduce the anesthetic gas concentrations during pediatric anesthesia induction. The investigators are interested in checking if the new technique also has an influence in decreasing the level of Sevoflurane breathed in by the anesthesiologist.The investigators purpose is to detect the presence of desfluoroisopropanolol in the urine of ten anesthesiologists who used sevoflurane to induce children with a mask during an eight-hour session in the induction room (IR) One session will be conducted without the use of the air extractor and the other with the air extractor. After 24 hours, a urine sample will be taken and sent to the Toxicology Unit.",[25],[177,178],"sevofluorane,","hexacloroisopropanolol","NOT_YET_RECRUITING","2024-07-02",{"date":182,"type":32},"2024-07-05",{"date":158,"type":21},{"date":60,"type":21},{"name":186,"class":187},"Bnai Zion Medical Center","OTHER_GOV"]